lino Biotech AG was founded in 2020.
With the support of Hoffman-La Roche AG, we are bringing the benefits of focal molography to the drug discovery market. We are happy to introduce our board members, bringing together numerous years of experience in building life science companies, as well as licensing deals and investment strategies.

Dr. Babette Güldenpfennig

Babette Güldenpfennig, Ph.D., joined Roche Diagnostics in 2014. She became Head of the Global Licensing Team in the same year after having supported the partnering activities of the newly established Sequencing Unit for a few months. Under her responsibility, the Licensing Team leads and conducts all licensing/partnering activities for the Diagnostic Division. In this context, Babette also drove and managed the spin-out of lino Biotech AG. Babette have brought more than fifteen years of hands-on experience in starting and managing start-up businesses to Roche having worked for Molecular Partners (listed at SIX) and Kuros Biosurgery (listed as Kuros Bioscience at SIX) which she also co-founded. As member of the executive management team of Kuros she was responsible for licensing, legal and BD matters. During that time and over the course of more than a decade, she supported the company in its maturation from the first negotiations of the foundational licensing agreements to its initial public offering. With a Ph.D. in chemistry from the ETH Zürich, Babette joined at the beginning of her career one of the largest patent law firms in Switzerland, Hepp Wenger Ryffel, where she worked as patent attorney while conducting formal training in intellectual property law.

Monique Schiersing

Monique is a Senior Investment Director at the Roche Venture Fund. Former roles include serving as the Chief Operating Officer at Inthera Bioscience AG, a previous Director position at Roche Venture Fund from 2009 to 2018, and a principal position with BankInvest’s BioMedical Ventures Group in Copenhagen.
In addition, Monique’s background includes several years in Roche’s Pharma business development group, and various other positions in academia, biotech and venture capital, both in Switzerland and the San Francisco Bay Area. Monique holds a M.Sc. in microbiology from the University of Zurich (Switzerland) and an MBA from the University of San Francisco.

Dr. Robert Wicke

Robert is currently CEO of Halo Labs, a life science company specializing in high-throughput protein characterization and identification. Before Halo, Robert was General Manager of Pall ForteBio responsible for growing the company from $20M to $50M+ in four years. Robert was also the Senior VP of Instrumentation R&D at Pall Corporation and a corporate M&A member, responsible for all instrumentation R&D across Pall worldwide. Robert was VP of Product Development and Operations for ForteBio from 2007 to 2012 where he helped grow the company 10x in four years and then exit the company for over $160M. Before that, Robert was at Molecular Devices Corporation, where he was Vice President of Product Development, being on the executive team that helped the $615M acquisition by MDS. Previously he was at Axon Instruments, Inc. for 13 years, as Vice President of Software Engineering, helping be the first private company to IPO on the Australian stock market, and was part of the $140+ million acquisition by Molecular Devices.

Seppo Mäkinen

Seppo Mäkinen – with 35 years´ experience in international venture capital industry (Sitra, BioFund, Merieux Development, Pathena) and expert with over 40 international board positions on e-health/MedTech/diagnostics (e.g. Wallac – PerkinElmer, Konelab – ThermoFisher, Exiqon – Qiagen). He is currently board member in several companies within healthcare service, e-health and diagnostics. Seppo has successfully listed over ten companies on international stock exchanges and has built up several success stories within medical / diagnostics industry in Europe.

Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and research tool expert driven by the goal to support the development and successful commercialization of life science innovations. He has extensive founder and executive management experience in taking companies from start to success exit. Following completing his Ph.D. in Biochemistry & Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey and subsequently worked with the turn-around specialist Droege & Comp., serving mainly clients from the pharma and chemistry industry in Germany and Switzerland. In 2008 he founded an independent Life Sciences consultancy in Germany where, to date, a team of international experts identify, fund and build innovative business opportunities. To date, three co-founded companies were successfully exited. Dr. Stange is also named investor on several granted and pending patents.